| Inhibition of actin polymerization decreases osteogeneic differentiation of mesenchymal stem cells through p38 MAPK pathway H Sonowal, A Kumar, J Bhattacharyya, PK Gogoi, BG Jaganathan Journal of Biomedical Science 20 (1), 1-10, 2013 | 96 | 2013 |
| Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity H Sonowal, PB Pal, JJ Wen, S Awasthi, KV Ramana, SK Srivastava Scientific reports 7 (1), 3182, 2017 | 77 | 2017 |
| Aldose reductase regulates hyperglycemia-induced HUVEC death via SIRT1/AMPK-α1/mTOR pathway PB Pal, H Sonowal, K Shukla, SK Srivastava, KV Ramana Journal of molecular endocrinology 63 (1), 11-25, 2019 | 68 | 2019 |
| Aldose reductase mediates NLRP3 inflammasome–initiated innate immune response in hyperglycemia-induced Thp1 monocytes and male mice PB Pal, H Sonowal, K Shukla, SK Srivastava, KV Ramana Endocrinology 158 (10), 3661-3675, 2017 | 47 | 2017 |
| Aldose reductase inhibitor, fidarestat regulates mitochondrial biogenesis via Nrf2/HO-1/AMPK pathway in colon cancer cells K Shukla, H Sonowal, A Saxena, KV Ramana, SK Srivastava Cancer letters 411, 57-63, 2017 | 42 | 2017 |
| 4-hydroxy-trans-2-nonenal in the regulation of anti-oxidative and pro-inflammatory signaling pathways H Sonowal, KV Ramana Oxidative medicine and cellular longevity 2019, 2019 | 35 | 2019 |
| Didymin prevents hyperglycemia-induced human umbilical endothelial cells dysfunction and death K Shukla, H Sonowal, A Saxena, KV Ramana Biochemical pharmacology 152, 1-10, 2018 | 32 | 2018 |
| Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction H Sonowal, P Pal, K Shukla, A Saxena, SK Srivastava, KV Ramana Biochemical pharmacology 150, 181-190, 2018 | 32 | 2018 |
| Aldose reductase inhibitor protects against hyperglycemic stress by activating Nrf2-dependent antioxidant proteins K Shukla, PB Pal, H Sonowal, SK Srivastava, KV Ramana Journal of diabetes research 2017, 2017 | 22 | 2017 |
| Didymin by suppressing NF-κB activation prevents VEGF-induced angiogenesis in vitro and in vivo K Shukla, H Sonowal, A Saxena, KV Ramana Vascular Pharmacology 115, 18-25, 2019 | 16 | 2019 |
| Aspalatone prevents VEGF-induced lipid peroxidation, migration, tube formation, and dysfunction of human aortic endothelial cells H Sonowal, PB Pal, K Shukla, KV Ramana Oxidative medicine and cellular longevity 2017, 2017 | 16 | 2017 |
| Vialinin a, an edible mushroom-derived p-terphenyl antioxidant, prevents vegf-induced neovascularization in vitro and in vivo H Sonowal, K Shukla, S Kota, A Saxena, KV Ramana Oxidative medicine and cellular longevity 2018, 2018 | 15 | 2018 |
| Development of aldose reductase inhibitors for the treatment of inflammatory disorders and cancer: Current drug design strategies and future directions H Sonowal, KV Ramana Current Medicinal Chemistry 28 (19), 3683-3712, 2021 | 12 | 2021 |
| Aldose reductase regulates doxorubicin-induced immune and inflammatory responses by activating mitochondrial biogenesis H Sonowal, A Saxena, S Qiu, S Srivastava, KV Ramana European Journal of Pharmacology 895, 173884, 2021 | 9 | 2021 |
| 2′-Hydroxyflavanone prevents LPS-induced inflammatory response and cytotoxicity in murine macrophages H Sonowal, KV Ramana Toxicology in Vitro 69, 104966, 2020 | 8 | 2020 |
| Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα H Sonowal, H Zhang, W Rice, SB Howell Biochemical pharmacology 195, 114861, 2022 | 3 | 2022 |
| Transcriptional factor modulation by lipid peroxidation-derived aldehydes A Saxena, H Sonowal, KV Ramana The Molecular Nutrition of Fats, 419-431, 2019 | 3 | 2019 |
| Contribution of Aldose Reductase-Mediated Oxidative Stress Signaling in Inflammatory Lung Diseases H Sonowal, A Saxena, KV Ramana Oxidative Stress in Lung Diseases: Volume 1, 225-246, 2019 | 2 | 2019 |
| Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiomyopathy H Sonowal, PB Pal, SK Srivastava, KV Ramana Cancer Research 77 (13_Supplement), 1052-1052, 2017 | 1 | 2017 |
| PB1766: IN VITRO ACQUIRED RESISTANCE TO THE ORAL MYELOID KINASE INHIBITOR TUSPETINIB CREATES SYNTHETIC LETHAL VULNERABILITY TO VENETOCLAX H Sonowal, R Bejar, W Rice, S Howell HemaSphere 7 (S3), e30384d0, 2023 | | 2023 |
Ramana KVUniversity of Texas Medical branchVerified email at utmb.edu
